Review Article

Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?

Table 2

Randomized phase I/II and III trials with nab-paclitaxel in aPC.
(a) Phase I/II

ArmsPtsMTDRR (%) Median OS (months)
1 year survival (%)

von Hoff et al., 2011 [31] (First line) Gemcitabine1000 mg/sqmNab-paclitaxel100 mg/m2 q3w
125 mg/m2 q3w
150 mg/m2 q3w
20
44
3
X4812.248

(b) Phase III

ArmsPtsORR
(%)
Median TTP
(MO)
PFSOSAEs (%)
Median
(MO)
1 yr
(%)
Median
(MO)
1 yr
(%)
2 yr
(%)
Grade ≥ III neutropenia Fatigue Neuropathy
  <.001   <.001   <.001   <.001   <.001

Von Hoff et al., 2011 [32]
(first line)
Nab-paclitaxel
125 mg/m2 qw
followed
Gemcitabine
1000 mg/sqm qw
431995.15.5168.5359381717
Gemcitabine
1000 mg/sqm qw
430313.63.796.72242771

P: P value; nd: not done; AEs: adverse events; MTD: maximum tolerated dose; ORR: overall responce rate; RR: response rate; TTP: time to progression; PFS: progression-free survival; OS: overall survival; MDR: median duration of response.